Generic Somavert Availability

Somavert is a brand name of pegvisomant, approved by the FDA in the following formulation(s):

SOMAVERT (pegvisomant - injectable;subcutaneous)

  • Manufacturer: PHARMACIA AND UPJOHN
    Approval date: March 25, 2003
    Strength(s): 10MG/VIAL [RLD], 15MG/VIAL [RLD], 20MG/VIAL [RLD]

Has a generic version of Somavert been approved?

No. There is currently no therapeutically equivalent version of Somavert available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Somavert. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Human growth hormone variants
    Patent 5,849,535
    Issued: December 15, 1998
    Inventor(s): Cunningham; Brian C. & Lowman; Henry B. & Wells; James A. & Clark; Ross G. & Olson; Kenneth & Fuh; Germaine G.
    Assignee(s): Genentech, Inc.
    Human growth hormone variants, DNA encoding the variants, vectors, host cells, pegylated forms of the variants, as well as methods of making the variants are disclosed.
    Patent expiration dates:
    • March 25, 2017
      ✓ 
      Drug substance
  • Method for inhibiting growth hormone action
    Patent 6,057,292
    Issued: May 2, 2000
    Inventor(s): Cunningham; Brian C. & Lowman; Henry B. & Wells; James A. & Clark; Ross G. & Olson; Kenneth & Fuh; Germaine G.
    Assignee(s): Genentech, Inc.
    Human growth hormone variants are disclosed having enhanced affinity for the growth hormone receptor. Also disclosed are human growth hormone variants conjugated to one or more chemical groups, such as poly(ethylene glycol), which is believed to prolong the in vivo half-life of the variants.
    Patent expiration dates:
    • September 21, 2015
      ✓ 
      Patent use: ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web2)